ArticleThe EMBO journal1990
Genetic ablation of a mouse gene expressed specifically in brain.
Article in The EMBO journal, 1990. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 75 citations in OpenAlex.
- Secretogranin III: a promising therapeutic target for intraocular neovascular lesions.International ophthalmology · 2025Review
- Feasibility of Ex Vivo Ligandomics.Biomolecules · 2025Article
- Pathophysiology of Retinopathy of Prematurity.Annual review of vision science · 2023Review
- Secretogranin III Selectively Promotes Vascular Leakage in the Deep Vascular Plexus of Diabetic Retinopathy.International journal of molecular sciences · 2023Article
- Neurovascular abnormalities in retinopathy of prematurity and emerging therapies.Journal of molecular medicine (Berlin, Germany) · 2022Review
- Comparative ligandomics implicates secretogranin III as a disease-restricted angiogenic factor in laser-induced choroidal neovascularization.The FEBS journal · 2022Article
- Safety and Efficacy of Systemic Anti-Scg3 Therapy to Treat Oxygen-Induced Retinopathy.Frontiers in bioscience (Landmark edition) · 2022Article
- Secretogranin III stringently regulates pathological but not physiological angiogenesis in oxygen-induced retinopathy.Cellular and molecular life sciences : CMLS · 2022Article
- Selectively targeting disease-restricted secretogranin III to alleviate choroidal neovascularization.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022Article
- Neurovascular regulation in diabetic retinopathy and emerging therapies.Cellular and molecular life sciences : CMLS · 2021Review
- Concurrent Physiological and Pathological Angiogenesis in Retinopathy of Prematurity and Emerging Therapies.International journal of molecular sciences · 2021Review
- Expression Pattern of theThe journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2021Article
- Anti-secretogranin III therapy of oxygen-induced retinopathy with optimal safety.Angiogenesis · 2019Article
- Secretogranin III as a novel target for the therapy of choroidal neovascularization.Experimental eye research · 2019Article
- Ligandomics: a paradigm shift in biological drug discovery.Drug discovery today · 2018Review
- Secretogranin III: a diabetic retinopathy-selective angiogenic factor.Cellular and molecular life sciences : CMLS · 2018Review
- Secretogranin III promotes angiogenesis through MEK/ERK signaling pathway.Biochemical and biophysical research communications · 2018Article
- Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy.The Journal of experimental medicine · 2017Article
- Expression of Secretogranin III in Chicken Endocrine Cells: Its Relevance to the Secretory Granule Properties of Peptide Prohormone Processing and Bioactive Amine Content.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2015Article
- A large form of secretogranin III functions as a sorting receptor for chromogranin A aggregates in PC12 cells.Molecular endocrinology (Baltimore, Md.) · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
The 1B1075 gene was initially identified from a cDNA clone of a rat brain messenger RNA expressed in particular subsets of CNS neurons and pituitary cells. Although the protein encoded by this gene is of unknown function, its sequence suggests that it may be related to secretogranin proteins, which are found in association with secretory granules in a variety of peptidergic endocrine and neuronal cells. Here we show that the mouse 1B1075 gene is located between the dilute (d) and short ear (se) genes on chromosome 9. Many different deletion mutations have previously been isolated in the genetic region that includes these genes. By producing mice carrying two deletions that overlap at the 1B1075 locus, the gene for this brain-specific message can be completely eliminated from otherwise viable animals. The animals missing the 1B1075 gene provide an important new tool for determining the function of this gene in the brain. In addition, these results provide a new molecular entry point for detailed characterization of other genes in the d-se region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.